CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
APM Graft (BIOTAPE XMTM) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01353495
NCT01353495N/ACompleted

A Prospective, Randomized Comparative Parallel Study of Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers

Stryker Trauma and Extremities·interventional·Posted May 13, 2011·Updated Jun 14, 2021

In Brief

A clinical study evaluating APM Graft (BIOTAPE XMTM) and Wound Debridement for Diabetic Foot Ulcers. Completed, enrolled 39 participants across 2 sites.

Detailed Summary

Have indolent diabetic ulcers completely healed by the Acellular Porcine Dermal Matrix (APM) in 12 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 13, 2011
Enrollment StartApr 1, 2010
Primary CompletionOct 1, 2010
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.1 years ago

Interventions

APM Graft (BIOTAPE XMTM)device

Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.

Wound Debridementother

Wounds debrided in both arms of study